Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Zynga (NASDAQ: ZNGA ) , a developer and marketer of online social games, dropped as much as 14% after the company announced plans to cut jobs and guided toward the low end of its previous bookings forecast.
So what: Zynga announced that it plans to cut a sizable 520 jobs -- roughly 18% of its workforce -- by August in order to save $70 million to $80 million annually. The move is being made as gaming competition and the costs of game development are steadily rising. The cuts will encompass all divisions of its workforce. Zynga reaffirmed its second-quarter EPS forecast, however, it also commented that bookings will be in the lower half of its previous forecast because many games outside of its Farmville franchise are underperforming. Despite the underperformance, Zynga also stuck to its previous full-year EBITDA guidance.
Top 5 Performing Stocks To Own Right Now: Amphenol Corporation(APH)
Amphenol Corporation engages in the design, manufacture, and marketing of electrical, electronic, and fiber optic connectors; interconnect systems; and coaxial and specialty cables worldwide. Its Interconnect Products and Assemblies segment produces connectors and connector assemblies primarily for the communications, aerospace, industrial, and automotive markets. This segment provides connector and cable assembly products used in communication applications; smart card acceptor and other interconnect devices used in mobile telephones; set top boxes to facilitate reading data from smart cards; fiber optic connectors used in fiber optic signal transmission; backplane and input/output connectors and assemblies used for servers and data storage devices and linking personal computers and peripheral equipment; sculptured flexible circuits used for integrating printed circuit boards; and hinge products used in mobile phone and other mobile communication devices. It also designs a nd produces radio frequency connector products and antennas used in telecommunications, computer and office equipment, instrumentation equipment, local area networks, and automotive electronics. The company?s Cable Products segment produces coaxial cable and connector products used in cable television systems, including full service cable television/telecommunication systems; radio frequency and fiber optic interconnect components for full service cable television/ telecommunication networks; and data cables and specialty cables used to connect internal components in systems with space and component configuration limitations. Amphenol Corporation markets its products directly, as well as through manufacturers? representatives and distributors to original equipment manufacturers, contract manufacturers, cable system operators, and telecommunication companies. The company was founded in 1932 and is headquartered in Wallingford, Connecticut.
Advisors' Opinion:- [By Pat Racaniello]
Amphenol Corp (APH) is our technology pick, a manufacturer of specialty cable and various connectors, including fiber optic ones, for use in electronic devices and the cable television industry. Near the lower band of the 52 week band ($40.44 - $59.11), the last traded price of $43.27 represents an excellent buy opportunity considering the stock is so far below the moving averages (50,100, 200).
The main competition for companies such as Amphenol comes from Taiwanese component makers, that compete at a lower price. Amphenol has a solid market reputation and compared with Molex (MOLX), the free cash flow margin is far ahead at 10% compared to 5% for the latter. Price to earnings is on the industry mark at 14 times, but the concern lies in the dividend payout which is basically nothing (1.91) compared to the industry (26.91).
Top 5 Performing Stocks To Own Right Now: NovaBay Pharmaceuticals Inc. (NBY)
NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. Its products include Aganocide compounds comprising NVC-422 that are synthetic molecules for the treatment of impetigo and adenoviral conjunctivitis, as well as for reducing the incidence of urinary catheter blockage and encrustation, and the associated urinary tract infections. The company is also involved in developing NeutroPhase, a solution for cleansing and debriding wounds. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Advisors' Opinion:- [By CRWE]
NovaBay(r) Pharmaceuticals, Inc. (Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide(r) compounds for the local non-systemic treatment and prevention of infections, reported that Tom Paulson, Chief Financial Officer, will present at the Rodman & Renshaw 14th Annual Healthcare Conference held September 9-11, 2012, in New York, NY.
Best Cheap Companies To Invest In Right Now: Vertex Pharmaceuticals Incorporated(VRTX)
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a prescription medicine used for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection; and Ivacaftor, a prescription medicine used for the treatment of cystic fibrosis. The company markets its products under the INCIVEK brand name in the United States and Canada; INCIVO brand in the United Kingdom, Germany, France, Sweden, Austria, Finland, Denmark, Switzerland, and Norway; KALYDECO brand in the United States; and TELAVIC brand in Japan. Its drug candidates comprise VX-222, a Phase II clinical trial drug candidate, and ALS-2200 and ALS-2158, a Phase I clinical trial drug candidates that are designed to inhibit the replication of HCV; VX-809 and VX-661, a Phase II clinical trial drug candidates that improve the function of defective cystic fibro sis; VX-509, a Phase II clinical trial drug candidate for the treatment of patients with rheumatoid arthritis and other immune-mediated inflammatory diseases; VX-765, a Phase II clinical trial drug for the treatment of epilepsy; and VX-787, an investigational drug candidate for the treatment of influenza A. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Melly Alazraki]
Vertex Pharmaceuticals (VRTX)topped the list with a 38.4% return as of Wednesday's close of $48.48. This $9.8 billion market capnon-profitablecompany is all promise. It is itspipelinethat's drawing investors, especially thehepatitis C treatment telaprevirandpotential cystic fibrosis drug VX-770.
Both diseases present large market opportunities: Liver disease caused by the hepatitis C virusaffects 3.2 million individualsin the U.S. and as many as 100 million people worldwide. Cystic fibrosis is an inherited genetic disease that affects about 30,000 people in the U.S. and has few treatment options.
Analysts ! have favored the stock, with aconsensus buy recommendation. However, just on Thursday, Vertex announcedtwomore telaprevir studyresultsthat did not impress investors and the stock declined 2% to $47.50. Also, Vertex is not without competitors and is in a race with Merck (MRK) and its experime ntal Hep C drug boceprevir to be the first to reach the market.
The stock's 52-week high of $52.13 was set on March 7, up from a low of $31.25 set on July 1, 2011. - [By Holly LaFon] Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex Pharmaceuticals Inc. has a market cap of $7.25 billion; its shares were traded at around $34.74 with and P/S ratio of 50.5. Vertex Pharmaceuticals Inc. had an annual average earnings growth of 13.3% over the past 10 years.
Hussman bought 1.8 million shares of Vertex in the fourth quarter at an average price of $35 per share.
Vertex�� shares sunk to their 52-week low of $26.50 in November 2011, off of a 52-week high of $58.57. Meanwhile, the company was working on FDA approval of the first drug to treat the underlying cause of cystic fibrosis, called Kalydeco. The drug received approval on January 31 and sent shares up 9%.
The company�� revenue has been slipping over the last several years, but saw a major jump in the third quarter of 2011 to $659.2 million, compared to $23.8 million for the third quarter of 2010. The increase was primarily a result of $419.6 million in net revenues from INCIVEK, a treatment for people with chronic genotype 1 hepatitis C, which became available in the third quarter. More than 25,000 Hepatitis C patients have begun treatment with INCIVEK as of Jan. 8, 2012. The company also received $200 in milestone revenues from collaborator Jannsen in the quarter.
In January, it set forth its 2012 key business objectives. Jeffrey Leiden, M.D., Ph.D., who will become Vertex's CEO on Feb. 1, 2012, commented, "Entering 2012, we are focused on becoming a sustainable business with strong revenues from INCIVEK and the planned global launch of KALYDECO for cystic fibrosis. Importantly, we are pursuing opportunities to further improve treatment with our all-oral regimens in development for hepatitis C and efforts to study our cystic fibrosis medicines in a larger group of people with this devastating disease. As these and other pipeline programs advance, we will manage our business with financial discipline and focused investme! nt to ensure the greatest benefit for patients waiting for new treatments and for our shareholders." - [By TheStreet Staff]
Vertex Pharma's (VRTX ) cystic fibrosis drug Kalydeco will be approved. More importantly, studies testing Kalydeco combined with other Vertex's cystic fibrosis drugs will show strong benefit in a larger swath of patients. Vertex becomes a cystic fibrosis company. Hepatitis C? What's that?
Correct. Kalydeco was approved in January -- in my opinion, the most important drug approval in 2012. The Kalydeco-VX-809 combination study was successful, even though the Street is still debating the magnitude of the regimen's benefit to cystic fibrosis patients
Top 5 Performing Stocks To Own Right Now: Dorman Products Inc.(DORM)
Dorman Products, Inc. supplies automotive replacement parts, fasteners, and service line products primarily for the automotive aftermarket. The company offers approximately 128,000 products comprising original equipment dealer parts, which include intake manifolds, exhaust manifolds, oil cooler lines, window regulators, radiator fan assemblies, power steering pulleys, and harmonic balancers; and replacement parts, such as window handles and switches, door hardware, interior trim parts, headlamp aiming screws and retainer rings, radiator parts, battery hold-down bolts and repair kits, valve train parts, and power steering filler caps. It also provides application specific and general automotive hardware, such as body hardware, general automotive fasteners, oil drain plugs, and wheel hardware; a selection of electrical connectors, wires, tools, testers, and accessories; and a line of home hardware and home organization products designed for retail merchandisers. In addition, the company offers a brake and clutch program; remanufactured automotive replacement parts, such as transfer case modules and instrument clusters; and heavy duty aftermarket parts for class 4-8 heavy vehicles, including coolant tubes, door handles and other body parts, fluid reservoirs, headlights and lighting, hood components, window regulators, and wiper transmissions. It sells its products under the OE Solutions, HELP!, AutoGrade, FirstStop, Conduct-Tite!, Pik-A-Nut, and HD Solutions brand names through automotive aftermarket retailers; national, regional, and local warehouse distributors; specialty markets; and salvage yards in the United States, Mexico, Europe, the Middle East, Asia, and Canada. The company, formerly known as R&B, Inc., was founded in 1978 and is headquartered in Colmar, Pennsylvania.
Top 5 Performing Stocks To Own Right Now: Alvarion Ltd.(ALVR)
Alvarion Ltd. supplies top-tier carriers, Internet service providers (ISPs), and private network operators with solutions based on the worldwide interoperability for Microwave Access (WiMAX) standard, as well as other wireless broadband solutions. The company provides WiMAX and non-WiMAX wireless broadband systems, and launched 250 commercial WiMAX deployments worldwide. Its solutions are designed to cover a range of frequency bands with fixed, portable, and mobile applications to enable the delivery of personal broadband services, business and residential broadband access, corporate virtual private network (VPN), toll quality telephony, mobile base station feeding, hotspot coverage extension, and services for various vertical markets, such as municipalities, public safety, mining, utilities, video surveillance, and border control. The company?s business mainly focuses on solutions, based on the WiMAX standard, that are used for primary wireless broadband access. In addit ion, Alvarion sells its non-WiMAX products, which address point-to-point and point-to-multipoint architectures for various end-user profiles, including residential, small office/home office, small/medium enterprises, multi-tenant/multi-dwelling units, and large enterprises, as well as provides network management solutions for its wireless solutions. Its solutions provide high-speed wireless ?last mile? connection to the Internet for homes and businesses in both developed and emerging markets. The company was formerly known as BreezeCOM Ltd. and changed its name to Alvarion Ltd. as result of merger with Floware Wireless Systems Ltd. in August 2001. Alvarion Ltd. was founded in 1992 and is headquartered in Tel Aviv, Israel.
Advisors' Opinion:- [By Sy_Harding]
This is a backdoor play on the growth in the developing world. The company supplies the WiMax networks that allow people in the developing world to get Internet access. This will be a high growth area but also at $3.80 a share, Alvarion is dirt cheap. It has $2.50 a share in cash in the bank, no debt, and is expected to earn 14 cents a share next year. Trading at less than 10 times earnings (when you back out the cash) and with the safe cushion of the cash, this stock is very attractive.
No comments:
Post a Comment